Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01650350 · ClinicalTrials.gov registry record · Phase 2
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
A Phase 2 study, sponsored by Brown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01650350 is a Phase 2 study that was terminated before completion, run by Brown University. The registered enrollment target is 7 participants.
The verdict
NCT01650350, a Phase 2 study, was terminated before completion, sponsored by Brown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
will scientifically evaluate whether Low Dose Naltrexone (LDN) has activity in refractory solid tumors within the context of a phase II clinical study
Interventions
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01650350
The ClinicalTrials.gov registry entry for NCT01650350 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Naltrexone is the first listed.
NCT01650350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01650350 about?
NCT01650350 is a clinical study titled "Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer". will scientifically evaluate whether Low Dose Naltrexone (LDN) has activity in refractory solid tumors within the context of a phase II clinical study
What is the current status of trial NCT01650350?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2012-11. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01650350?
The interventions under investigation include: Naltrexone (DRUG).
Who is sponsoring clinical trial NCT01650350?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.